THARROS

Full Title: A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)

Aim: This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.

We are now recruiting participants for this study. If you think you are eligible or know someone who may be eligible, please email hcl.trials@nhs.net

Could I be eligible to take part?
You must	You must not
– Be aged between 40-80 years.  – Have good inhaler-use technique.  – Be diagnosed with COPD.  – Be a current or former smoker. Have a cardiovascular risk.	– Have any other respiratory condition aside from COPD.   – Have had a heart or lung transplant or actively be listed for a transplant. – Have a history of lung cancer and/or treatment for this in the last 5 years.  – Have used maintenance Inhaled Corticosteroids in the last 12months.  – Be unable to comply with study procedures, restrictions, or requirements.  – Be a currently pregnant female.